Guggenheim Says Bausch Health Companies (BHC) Sell-Off 'Overdone'

Go back to Guggenheim Says Bausch Health Companies (BHC) Sell-Off 'Overdone'

Cowen Defends Bausch Health Companies (BHC); 'Add Here'

February 19, 2020 11:37 AM EST

Cowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC), saying there is no change to the thesis and investors should add here.

The analyst commented, "Q4 revs were slightly above the Street, while earnings... More

Bausch Health Co. Inc. (BHC) Posts Q4 Adjusted EBITDA of $898 Million, Revs Beat

February 19, 2020 7:02 AM EST

Bausch Health Co. Inc. (NYSE: BHC) reported Q4 Adjusted EBITDA of $898 Million. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.2 billion.

GUIDANCE:

Bausch Health Co. Inc. sees FY2020 revenue of $8.65-8.85 billion, versus the consensus of... More